DaVita (DVA) Stock Forecast, Price Target & Predictions
DVA Stock Forecast
DaVita stock forecast is as follows: an average price target of $125.50 (represents a -23.27% downside from DVA’s last price of $163.56) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
DVA Price Target
The average price target for DaVita (DVA) is $125.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $90.00. This represents a potential -23.27% downside from DVA's last price of $163.56.
DVA Analyst Ratings
According to 3 Wall Street analysts, DaVita's rating consensus is 'Hold'. The analyst rating breakdown for DVA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DaVita Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Kevin Fischbeck | Bank of America Securities | $145.00 | $133.53 | 8.59% | -11.35% |
| May 06, 2024 | Andrew Mok | Barclays | $150.00 | $134.45 | 11.57% | -8.29% |
| Oct 31, 2022 | Sarah James | Barclays | $81.00 | $70.54 | 14.83% | -50.48% |
| Aug 19, 2022 | Andrew Mok | UBS | $117.00 | $93.10 | 25.67% | -28.47% |
| Jun 28, 2022 | David MacDonald | Truist Financial | $90.00 | $79.44 | 13.29% | -44.97% |
The latest DaVita stock forecast, released on Aug 07, 2024 by Kevin Fischbeck from Bank of America Securities, set a price target of $145.00, which represents a 8.59% increase from the stock price at the time of the forecast ($133.53), and a -11.35% decrease from DVA last price ($163.56).
DaVita Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $145.00 | $147.50 |
| Last Closing Price | $163.56 | $163.56 | $163.56 |
| Upside/Downside | -100.00% | -11.35% | -9.82% |
In the current month, the average price target of DaVita stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DaVita's last price of $163.56. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 06, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jan 05, 2023 | CFRA | - | Hold | Upgrade |
| Aug 19, 2022 | UBS | - | Buy | Upgrade |
| Jun 28, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
DaVita's last stock rating was published by Barclays on May 06, 2024. The company gave DVA a "Equal-Weight" rating, the same as its previous rate.
DaVita Financial Forecast
DaVita Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.12B | $3.00B | $2.87B | $2.92B | $2.95B | - | $2.82B | $2.94B | $2.94B | $2.92B | $2.82B | $2.91B | $2.92B | $2.88B | $2.84B | $2.90B | $2.90B |
| Avg Forecast | $3.48B | $3.49B | $3.42B | $3.33B | $3.42B | $3.42B | $3.31B | $3.24B | $3.27B | $3.25B | $3.15B | $3.03B | $3.01B | $3.02B | $2.95B | $2.84B | $2.93B | $2.98B | $2.93B | $2.89B | $2.91B | $2.91B | $2.87B | $2.84B | $2.93B | $2.94B | $2.93B | $2.84B | $2.92B | $2.85B |
| High Forecast | $3.53B | $3.54B | $3.46B | $3.37B | $3.47B | $3.47B | $3.35B | $3.28B | $3.31B | $3.32B | $3.20B | $3.07B | $3.04B | $3.04B | $2.99B | $2.88B | $2.97B | $3.02B | $2.93B | $2.91B | $2.93B | $2.93B | $2.89B | $2.85B | $2.95B | $2.96B | $2.95B | $2.86B | $2.94B | $2.87B |
| Low Forecast | $3.42B | $3.43B | $3.36B | $3.27B | $3.36B | $3.36B | $3.25B | $3.18B | $3.21B | $3.22B | $3.10B | $2.97B | $2.99B | $3.00B | $2.90B | $2.79B | $2.88B | $2.92B | $2.93B | $2.87B | $2.90B | $2.90B | $2.85B | $2.82B | $2.91B | $2.92B | $2.91B | $2.82B | $2.90B | $2.83B |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.01% | 1.00% | 0.99% | - | 0.98% | 1.01% | 1.01% | 1.02% | 0.99% | 0.99% | 1.00% | 0.98% | 1.00% | 0.99% | 1.02% |
DaVita's average Quarter revenue forecast for Dec 23 based on 4 analysts is $3.01B, with a low forecast of $2.99B, and a high forecast of $3.04B. DVA's average Quarter revenue forecast represents a -3.62% decrease compared to the company's last Quarter revenue of $3.12B (Sep 23).
DaVita EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $664.71M | $590.34M | $493.47M | $442.52M | $501.30M | - | $509.47M | $561.79M | $637.75M | $675.35M | $609.47M | $549.33M | $599.96M | $593.09M | $612.76M | $632.54M | $623.39M |
| Avg Forecast | $696.75M | $698.32M | $683.56M | $665.68M | $684.57M | $684.20M | $661.77M | $647.15M | $653.81M | $649.60M | $630.50M | $642.08M | $601.75M | $603.92M | $590.47M | $583.71M | $586.34M | $604.45M | $587.06M | $530.64M | $438.74M | $549.50M | $473.72M | $472.95M | $519.27M | $341.26M | $287.96M | $433.76M | $507.55M | $347.08M |
| High Forecast | $706.47M | $708.06M | $693.09M | $674.97M | $694.12M | $693.75M | $671.01M | $656.18M | $662.93M | $663.72M | $639.30M | $770.49M | $607.77M | $608.50M | $598.70M | $700.45M | $594.51M | $725.34M | $587.06M | $636.77M | $526.49M | $659.40M | $568.46M | $567.53M | $623.12M | $409.52M | $345.56M | $520.51M | $609.06M | $416.49M |
| Low Forecast | $684.35M | $685.89M | $671.39M | $653.83M | $672.38M | $672.03M | $650.00M | $635.63M | $642.17M | $643.55M | $619.28M | $513.66M | $597.74M | $600.51M | $579.96M | $466.97M | $575.90M | $483.56M | $587.06M | $424.51M | $350.99M | $439.60M | $378.97M | $378.36M | $415.41M | $273.01M | $230.37M | $347.01M | $406.04M | $277.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.00% | 0.85% | 0.75% | 0.83% | - | 0.96% | 1.28% | 1.16% | 1.43% | 1.29% | 1.06% | 1.76% | 2.06% | 1.41% | 1.25% | 1.80% |
4 analysts predict DVA's average Quarter EBITDA for Dec 23 to be $601.75M, with a high of $607.77M and a low of $597.74M. This is -9.47% lower than DaVita's previous annual EBITDA (Sep 23) of $664.71M.
DaVita Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $246.63M | $178.69M | $170.67M | $113.16M | $164.69M | - | $162.12M | $249.43M | $259.75M | $293.82M | $237.40M | $254.00M | $217.54M | $201.60M | $239.59M | $244.87M | $143.27M |
| Avg Forecast | $293.51M | $381.01M | $375.30M | $314.30M | $226.44M | $303.37M | $274.35M | $227.04M | $195.09M | $242.27M | $230.52M | $223.44M | $144.98M | $178.91M | $151.84M | $203.13M | $83.02M | $271.76M | $189.14M | $184.66M | $164.56M | $247.05M | $225.17M | $202.18M | $192.36M | $119.01M | $110.88M | $180.92M | $215.37M | $109.76M |
| High Forecast | $298.84M | $387.92M | $382.10M | $320.00M | $230.55M | $308.87M | $279.33M | $231.16M | $198.63M | $250.17M | $234.70M | $268.13M | $158.24M | $195.73M | $154.60M | $243.76M | $84.52M | $326.11M | $189.14M | $221.60M | $197.47M | $296.47M | $270.20M | $242.62M | $230.83M | $142.81M | $133.06M | $217.10M | $258.44M | $131.72M |
| Low Forecast | $286.72M | $372.19M | $366.61M | $307.03M | $221.20M | $296.35M | $268.01M | $221.79M | $190.57M | $238.76M | $225.18M | $178.75M | $127.92M | $163.85M | $148.33M | $162.50M | $81.09M | $217.41M | $189.14M | $147.73M | $131.65M | $197.64M | $180.14M | $161.75M | $153.89M | $95.20M | $88.70M | $144.73M | $172.29M | $87.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | 1.18% | 0.84% | 1.36% | 0.61% | - | 0.88% | 1.52% | 1.05% | 1.30% | 1.17% | 1.32% | 1.83% | 1.82% | 1.32% | 1.14% | 1.31% |
DaVita's average Quarter net income forecast for Dec 23 is $144.98M, with a range of $127.92M to $158.24M. DVA's average Quarter net income forecast represents a -41.22% decrease compared to the company's last Quarter net income of $246.63M (Sep 23).
DaVita SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $376.88M | $364.02M | $331.61M | $379.71M | $365.45M | - | $294.82M | $322.72M | $293.10M | $298.09M | $281.43M | $304.52M | $363.28M | $316.21M | $263.58M | $278.43M | $298.74M |
| Avg Forecast | $380.29M | $381.15M | $373.09M | $363.33M | $373.64M | $373.44M | $361.20M | $353.22M | $356.85M | $354.55M | $344.13M | $406.33M | $328.44M | $329.62M | $322.28M | $369.39M | $320.03M | $306.64M | $320.42M | $335.81M | $283.28M | $278.77M | $228.44M | $239.68M | $337.09M | $272.46M | $173.91M | $199.03M | $244.88M | $228.87M |
| High Forecast | $385.60M | $386.46M | $378.29M | $368.40M | $378.85M | $378.65M | $366.24M | $358.14M | $361.83M | $362.26M | $348.93M | $487.60M | $331.73M | $332.13M | $326.78M | $443.27M | $324.49M | $367.97M | $320.42M | $402.97M | $339.93M | $334.52M | $274.13M | $287.61M | $404.51M | $326.95M | $208.70M | $238.83M | $293.86M | $274.64M |
| Low Forecast | $373.52M | $374.36M | $366.45M | $356.87M | $366.99M | $366.80M | $354.77M | $346.93M | $350.50M | $351.25M | $338.01M | $325.07M | $326.25M | $327.76M | $316.54M | $295.51M | $314.33M | $245.31M | $320.42M | $268.65M | $226.62M | $223.01M | $182.75M | $191.74M | $269.67M | $217.97M | $139.13M | $159.22M | $195.90M | $183.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 1.13% | 0.90% | 1.19% | 1.19% | - | 0.88% | 1.14% | 1.05% | 1.30% | 1.17% | 0.90% | 1.33% | 1.82% | 1.32% | 1.14% | 1.31% |
DaVita's average Quarter SG&A projection for Dec 23 is $328.44M, based on 4 Wall Street analysts, with a range of $326.25M to $331.73M. The forecast indicates a -12.85% fall compared to DVA last annual SG&A of $376.88M (Sep 23).
DaVita EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.70 | $1.96 | $1.89 | $1.26 | $1.81 | - | $1.68 | $2.47 | $2.48 | $2.76 | $2.18 | $2.27 | $1.80 | $1.65 | $1.92 | $1.89 | $1.38 |
| Avg Forecast | $3.30 | $4.28 | $4.22 | $3.53 | $2.55 | $3.41 | $3.08 | $2.55 | $2.19 | $2.72 | $2.59 | $1.95 | $1.63 | $2.01 | $1.71 | $1.18 | $0.93 | $1.77 | $2.09 | $1.87 | $1.80 | $2.25 | $2.17 | $1.79 | $1.87 | $1.44 | $1.32 | $1.48 | $1.66 | $1.24 |
| High Forecast | $3.36 | $4.36 | $4.30 | $3.60 | $2.59 | $3.47 | $3.14 | $2.60 | $2.23 | $2.81 | $2.64 | $1.98 | $1.78 | $2.20 | $1.74 | $1.20 | $0.95 | $1.80 | $2.09 | $1.88 | $1.81 | $2.27 | $2.19 | $1.80 | $1.88 | $1.45 | $1.33 | $1.49 | $1.68 | $1.25 |
| Low Forecast | $3.22 | $4.18 | $4.12 | $3.45 | $2.49 | $3.33 | $3.01 | $2.49 | $2.14 | $2.68 | $2.53 | $1.90 | $1.44 | $1.84 | $1.67 | $1.15 | $0.91 | $1.73 | $2.09 | $1.85 | $1.79 | $2.24 | $2.16 | $1.77 | $1.85 | $1.43 | $1.31 | $1.46 | $1.65 | $1.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34% | 1.15% | 1.61% | 1.35% | 1.02% | - | 0.90% | 1.37% | 1.10% | 1.27% | 1.22% | 1.22% | 1.25% | 1.25% | 1.30% | 1.14% | 1.11% |
According to 4 Wall Street analysts, DaVita's projected average Quarter EPS for Dec 23 is $1.63, with a low estimate of $1.44 and a high estimate of $1.78. This represents a -39.63% decrease compared to DVA previous annual EPS of $2.70 (Sep 23).
DaVita Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AMN | AMN Healthcare Services | $47.14 | $122.33 | 159.50% | Buy |
| CYH | Community Health Systems | $5.72 | $11.00 | 92.31% | Buy |
| SGRY | Surgery Partners | $31.00 | $47.50 | 53.23% | Buy |
| AMED | Amedisys | $96.91 | $143.38 | 47.95% | Hold |
| OPCH | Option Care Health | $31.99 | $38.00 | 18.79% | Buy |
| ACHC | Acadia Healthcare Company | $78.23 | $84.89 | 8.51% | Buy |
| EHC | Encompass Health | $93.25 | $93.17 | -0.09% | Buy |
| UHS | Universal Health Services | $232.56 | $208.47 | -10.36% | Hold |
| THC | Tenet Healthcare | $162.41 | $124.87 | -23.11% | Buy |
| DVA | DaVita | $163.56 | $125.50 | -23.27% | Hold |
| ENSG | Ensign Group | $152.73 | $114.25 | -25.19% | Buy |
| HCA | HCA Healthcare | $394.68 | $291.95 | -26.03% | Buy |
DVA Forecast FAQ
Is DaVita a good buy?
No, according to 3 Wall Street analysts, DaVita (DVA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of DVA's total ratings.
What is DVA's price target?
DaVita (DVA) average price target is $125.5 with a range of $90 to $150, implying a -23.27% from its last price of $163.56. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will DaVita stock go up soon?
According to Wall Street analysts' prediction for DVA stock, the company can go down by -23.27% (from the last price of $163.56 to the average price target of $125.5), down by -8.29% based on the highest stock price target, and down by -44.97% based on the lowest stock price target.
Can DaVita stock reach $200?
DVA's average twelve months analyst stock price target of $125.5 does not support the claim that DaVita can reach $200 in the near future.
What are DaVita's analysts' financial forecasts?
DaVita's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.39B (high $13.57B, low $13.15B), average EBITDA is $2.68B (high $2.72B, low $2.63B), average net income is $1.03B (high $1.05B, low $1.01B), average SG&A $1.46B (high $1.48B, low $1.44B), and average EPS is $11.59 (high $11.8, low $11.32). DVA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $13.72B (high $13.91B, low $13.47B), average EBITDA is $2.74B (high $2.78B, low $2.7B), average net income is $1.36B (high $1.39B, low $1.33B), average SG&A $1.5B (high $1.52B, low $1.47B), and average EPS is $15.34 (high $15.61, low $14.98).
Did the DVA's actual financial results beat the analysts' financial forecasts?
Based on DaVita's last annual report (Dec 2022), the company's revenue was $11.61B, which missed the average analysts forecast of $11.73B by -1.03%. Apple's EBITDA was $2.06B, missing the average prediction of $2.31B by -10.94%. The company's net income was $768.19M, beating the average estimation of $728.58M by 5.44%. Apple's SG&A was $1.36B, beating the average forecast of $1.28B by 5.64%. Lastly, the company's EPS was $8.26, beating the average prediction of $6.66 by 24.11%. In terms of the last quarterly report (Sep 2023), DaVita's revenue was $3.12B, beating the average analysts' forecast of $3.02B by 3.39%. The company's EBITDA was $664.71M, beating the average prediction of $603.92M by 10.07%. DaVita's net income was $246.63M, beating the average estimation of $178.91M by 37.86%. The company's SG&A was $376.88M, beating the average forecast of $329.62M by 14.34%. Lastly, the company's EPS was $2.7, beating the average prediction of $2.01 by 34.24%